Summary
The plasma and urine kinetics of rufloxacin were assessed in healthy volunteers after single (100, 200, 400 and 800 mg) and multiple (300 mg followed by 150 mg daily, Group 1, and 400 mg followed by 200 mg daily, Group 2) oral doses. The kinetics of a single oral dose of 800 mg was assessed in fasting and non-fasting subjects to assess the influence of food intake on drug absorption.
The AUCs were 134, 266 and 375 μg · h · ml−1 after 100, 200 and 400 mg, respectively. The AUC after 800 mg p. o. was 715 μg · h · ml −1 in fasting subjects and 614 μg · h · ml−1 in non-fasting subjects. The parameters of the model and the mean renal clearance values indicated some departure from linearity in rufloxacin kinetics. After multiple doses the plasma drug levels during the 6th treatment day were similar to those after the first dose in Group 1 and were about 30–40% higher after the first dose in Group 2. The half-lives after the last dose were much shorter than those estimated in the single dose studies (33–36 h and 50–80 h, respectively).
Similar content being viewed by others
References
Neuman M (1990) Rufloxacin's place among the fluoroquinolones. 7th Mediterrane an Congress of Chemotherapy, Barcelona, May 20–25
Segre G, Cerretani D, Cerri D, Moltoni L (1988) A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics. Drugs Exp Clin Res 14: 747
Neuman M, Sogni P, Michojoulos S et al. (1989) Single dose therapy of lower urinary tract infections (UTI) with rufloxacin, a long acting fluoroquinolone. 16th International Congress of Chemotherapy, Jerusalem, June 1–16
Bassetti M, Cruciani M, Danzi MC et al. (1990) Rufloxacin in the treatment of uncomplicated urinary tract infections. 7th Mediterranean Congress of Chemotherapy. Barcelona, May 20–25
Dirksen M, Focht J, Bruggink M et al. (1990) Rufloxacin (MF934) in the treatment of patients with an acute exacerbation of chronic bronchitis. 7th Mediterranean Congress of Chemotherapy, Barcelona, May 20–25
Boerema JBJ, Klietman W, Jol C et al. (1990) Treatment of chronic bacterial prostatitis with rufloxacin. 7th Mediterranean Congress of Chemotherapy, Barcelona, May 20–25
Fravolini A, Terni P, Mascellani G, Pagella PG, Segre G (1985) Pharmacokinetics of a new quinolone of the pyrido-benzothazine series. In: Ishigami J (ed), Antimicrobial Section I, Proceedings of the 14-th International Congress of Chemotherapy, Kyoto, University Tokyo Press, Tokyo, pp 640–641
Cecchetti V, Fravolini A, Fringuelli R, Mascellani G, Pagella P, Palmioli M, Segre G, Terni P (1987) Quinolone carboxylic acids. II. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyridol[1,2,3-de] [1, 4] benzothiazine-6-carboxilic acid. J Med Chem 30: 465
MKMODEL Manual, Copyright 1986, 1987, Nick Holford, Elsevier/Biosoft
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Segre, G., Cerretani, D., Moltoni, L. et al. Pharmacokinetics of rufloxacin in healthy volunteers. Eur J Clin Pharmacol 42, 101–105 (1992). https://doi.org/10.1007/BF00314928
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00314928